



NDA 210496/S-015

**SUPPLEMENT APPROVAL/
FULFILLMENT OF POSTMARKETING COMMITMENTS**

Array BioPharma Inc.,
a wholly owned subsidiary of Pfizer Inc.
Attention: Neeti P. Arora
Director, Pfizer Global Regulatory Sciences
275 North Field Drive
Lake Forest, IL 60045

Dear Neeti Arora:

Please refer to your supplemental new drug application (sNDA) dated and received April 14, 2023, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Braftovi (encorafenib) oral capsules.

This Prior Approval sNDA provides for revisions to the DRUG INTERACTIONS and CLINICAL PHARMACOLOGY sections of the Braftovi United States Prescribing Information (USPI).

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

FULFILLMENT OF POSTMARKETING COMMITMENTS

We have received your submission dated April 14, 2023, containing the final reports for the following postmarketing commitments listed in the June 27, 2018, approval letter.

- 3440-1 Conduct a clinical pharmacokinetic trial to evaluate the effect of repeat doses of a moderate CYP3A4 inducer on the repeat dose pharmacokinetics of encorafenib to assess the magnitude of decreased encorafenib exposure and to determine appropriate dosing recommendations. Design and conduct the trial in accordance with the FDA Guidance for Industry entitled, Clinical Drug Interaction Studies – Study Design, Data Analysis, and Clinical Implications (<https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf>).

- 3440-2 Conduct a clinical trial to evaluate the effect of repeat doses of encorafenib on the single dose pharmacokinetics of sensitive substrates of CYP1A2, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 to assess the magnitude of exposure change for sensitive substrates of the above CYP enzymes and to determine appropriate dosing recommendations. Design and conduct the trial in accordance with the FDA Guidance for Industry entitled Clinical Drug Interaction Studies – Study Design, Data Analysis, and Clinical Implications (<https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf>).

We have reviewed your submission and conclude that the above commitments were fulfilled.

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

We remind you that there is a postmarketing commitment listed in the June 27, 2018, approval letter that is still open.

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Christina Leach, Senior Regulatory Health Project Manager, at Christina.Leach@fda.hhs.gov or 240-402-6571.

Sincerely,

{See appended electronic signature page}

Steven Lemery, M.D., M.H.S.
Director
Division of Oncology 3
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

STEVEN J LEMERY
10/13/2023 01:30:50 PM